Literature DB >> 14681512

Medical management of benign prostatic hyperplasia--are two drugs better than one?

E Darracott Vaughan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14681512     DOI: 10.1056/NEJMe038154

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options.

Authors:  Jaspreet S Sandhu; E Darracott Vaughan
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.

Authors:  Vincent M Santillo; Franklin C Lowe
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  The effect of competing direct-to-consumer advertising campaigns on the use of drugs for benign prostatic hyperplasia: time series analysis.

Authors:  Sean C Skeldon; Katy B Kozhimannil; Sumit R Majumdar; Michael R Law
Journal:  J Gen Intern Med       Date:  2014-10-23       Impact factor: 5.128

Review 4.  How do I treat and follow my TUNA patients.

Authors:  Sas Barmoshe; Alexandre R Zlotta
Journal:  World J Urol       Date:  2006-07-21       Impact factor: 4.226

5.  Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload.

Authors:  Timothy D O'Connell; Philip M Swigart; M C Rodrigo; Shinji Ishizaka; Shuji Joho; Lynne Turnbull; Laurence H Tecott; Anthony J Baker; Elyse Foster; William Grossman; Paul C Simpson
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

Review 6.  Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance.

Authors:  Timothy D O'Connell; Brian C Jensen; Anthony J Baker; Paul C Simpson
Journal:  Pharmacol Rev       Date:  2013-12-24       Impact factor: 25.468

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.